This site is intended for health professionals only

Friday 20 September 2019
Share |

Topic: Latest News

September 20, 2019
The yardstick is published in Annals of Allergy, Asthma and Immunology and offers help on next steps when there is no clear cause of severe reactions
According to a new 'yardstick', there are people for whom diagnosis and treatment of anaphylaxis are difficult because the cause is unknown and therefore labelled 'idiopathic.'
 
September 20, 2019
The FAD is part of the final guidance to the NHS in England and Wales expected to be published in October 2019
Takeda has announced that the National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending Takhzyro®▼ (lanadelumab) subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.
 
The recommendation is only if:
  • patients are eligible for preventive C1-esterase inhibitor (C1-INH) treatment in line with NHS England’s commissioning policy
September 20, 2019
Results from the CONCLUDE trial were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes in Barcelona, Spain
According to new data from the CONCLUDE head-to-head trial, Tresiba® (insulin degludec) showed an overall lower risk of hypoglycaemia at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs. 
 
September 17, 2019
Assessors from the Joint Advisory Group (JAG) on Gastrointestinal Endoscopy, which is hosted by the Royal College of Physicians, visited the new unit at the Quadram Institute to ensure the Trust is meeting all regulatory requirements
The Norfolk and Norwich University Hospital’s endoscopy service has been described as the best in the country following an inspection.
 
The service, which moved into the state-of-the-art building in December, received high praise from assessors who were impressed by the design and found all endoscopists working to the “highest performance standards.”
 
September 17, 2019
Researchers have found that men who carry the BRCA2 gene fault were almost twice as likely to be diagnosed with prostate cancer than non-carriers
Men with the BRCA2 gene fault have an increased risk of prostate cancer and could benefit from PSA (prostate specific antigen) testing to help detect the disease earlier, according to researchers funded by Cancer Research UK.
 
Previous studies have shown that PSA is not a suitable test for screening for prostate cancer in the general population, and this remains the case. There are limitations to the PSA test - including false positives, false negatives and overdiagnosis.
 
September 17, 2019
In a paper published in the Journal of Medical Screening, researchers from King's College London and Queen Mary University of London have found that despite free cancer screening programmes, only 35% take part in all offered programmes
In England, women are invited for screening for three types of cancer concurrently in their sixties; for the last cervical screen before they exit the programme, for breast screening every three years, and for bowel screening every two years. 
 
This means that an average woman aged 60 can expect to receive five or six cancer screening invitations by the time she turns 65. In England, cancer screening is provided by the NHS free of charge.
 
September 12, 2019
NHS Digital’s Hospital Accident and Emergency Activity 2018/19 also shows that attendances for the 20% of the population living in the most deprived areas accounted for 27% of all A&E attendances
There were more than twice as many attendances to Accident and Emergency departments in England for the 10% of the population living in the most deprived areas (3.1 million), compared with the least deprived 10% (1.5 million) in 2018-19.
 
September 12, 2019
Across all efficacy endpoints, benefits were observed in patients treated with Imfinzi plus chemotherapy vs. SoC.
Results presented at the Presidential Symposium of the IASLC 2019 World Conference on Lung Cancer have shown improved overall survival with Imfinzi in small cell lung cancer. 
 
September 12, 2019
In the ASPIRE I & II trials, esketamine nasal spray plus standard of care was generally well-tolerated with no new safety signals
Positive results from the Phase III ASPIRE I & II trials to evaluate the efficacy and safety of esketamine nasal spray have been presented at the European College of Neuropsychopharmacology.
 
September 12, 2019
The analysis included 474 patients presenting to the emergency department with acute coronary syndrome (myocardial infarction and unstable angina)
According to a study published in the European Journal of Cardiovascular Nursing, heart attack symptoms can be gradual or abrupt and both situations are a medical emergency. 
 
The study found that patients with gradual symptom onset took eight hours to get medical help compared to 2.6 hours for those with abrupt symptoms. A maximum delay of two hours is recommended to get fast treatment and the best outcomes; serious complications and death are more likely beyond this window.
 
September 12, 2019
At five years, patients who were treated with nivolumab experienced a five-fold increase in long-term overall survival (OS) benefit versus docetaxel, with OS rates of 13.4% versus 2.6%, respectively
Results from the pooled analysis of the CheckMate -017 and -057 studies of five-year overall survival in patients with previously-treated advanced non-small cell lung cancer have been announced. 
 
Among patients with an objective response to nivolumab, 32.2% continued to see a response at five years compared to 0% on docetaxel. The median duration of response was 19.9 months for nivolumab-treated patients versus 5.6 months for docetaxel.
 
September 9, 2019
The number of allergic diseases increases the risk of adult-onset asthma especially in individuals born after 1940, according to a study published in Allergy journal
A Finnish study found that the more allergic diseases an individual has, the higher the asthma risk.
 
Approximately one in ten Finns suffers from asthma. It is one of the most common chronic illnesses in Western countries. Allergy is a risk factor in childhood asthma but its significance to adult-onset asthma is not precisely known.
 
September 9, 2019
The antigen-specific liposome immunotherapy treatment helps restore immune cells to healthy function
People living with inflammatory autoimmune disease could benefit from an 'immune system reboot', and researchers have isolated specific cells to target.
 
The University of Queensland's Professor Ranjeny Thomas said the research findings give hope for similar new immunotherapies for people with diseases like rheumatoid arthritis and vasculitis.
 
"People with these diseases currently require daily medications to modify or suppress their immune system," she said.
September 9, 2019
The ECLS trial, conducted in Scotland with 12,209 patients, is believed to be the largest randomised controlled trial using blood biomarkers for the detection of lung cancer
Data has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis. 
 
In a randomised controlled trial of 12,209 people in Scotland at high risk of developing lung cancer, it was shown that more people were diagnosed at an early stage of the disease in the two years after taking the EarlyCDT Lung test than those in the control arm who received standard clinical care. 
September 6, 2019
The decision extends the indication of Lonsurf in the EU, which already is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer
Servier and its partner Taiho Pharmaceutical have announced that the European Commission (EC) has approved the use of Lonsurf® (trifluridine/tipiracil) as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
 
September 5, 2019
The treatment is recommended for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations, and who have sufficient viable retinal cells

Novartis has announced that Luxturna® (voretigene neparvovec) has been recommended for use on the NHS as an option for treating RPE65-mediated inherited retinal dystrophies.
 

September 3, 2019
The document highlights how catheter ablation is revolutionising care for this group of common arrhythmias

The European Society of Cardiology (ESC) Guidelines on supraventricular tachycardia have been published in the European Heart Journal, and on the ESC website.

September 3, 2019

In just one year, around 115,000 cancer patients in England are diagnosed too late to give them the best chance of survival, according to new calculations from Cancer Research UK.

This means that nearly half of all cancers diagnosed with a known stage in England are diagnosed at stage 3 or 4. And of these, around 67,000 people are diagnosed at stage 4 -  leaving them with fewer treatment options and less chance of surviving their disease.

September 3, 2019
The guidelines were developed in collaboration with the European Association for the Study of Diabetes

New European Society of Cardiology (ESC) Guidelines on diabetes, pre-diabetes and cardiovascular diseases have been published.

September 3, 2019
For fuss-free measuring of lung function, the phone connects to a wireless spirometer and the app can register respiratory symptoms and provide visual feedback on treatment

A study by researchers at Karolinska Institutet shows that a treatment adjustment algorithm based on lung function and symptoms in a mobile phone can be an efficient tool in managing uncontrolled asthma.

The study is published in the European Respiratory Journal.

August 27, 2019
By studying human motor neurons derived from patients’ skin cells, the team hope to build scientific understanding that may underpin new treatments in the years to come

MSD and the Francis Crick Institute in London have entered into a collaboration to understand the causes of motor neurone disease and better understand difficult to treat diseases.

In the clinic, it’s devastating when I have to tell a patient they have motor neurone disease,” says Dr Rickie Patani, a research group leader at the Crick and UCL and consultant neurologist at the National Hospital for Neurology and Neurosurgery.

August 22, 2019
The findings suggest a pattern of risk that may be linked to differences in gut microbiome activity along the length of the bowel and reiterate the importance of judicious prescribing, say the researchers
Antibiotic use is linked to a heightened risk of colon suggests research published online in the journal Gut.
 
The findings suggest a pattern of risk that may be linked to differences in gut microbiome (bacteria) activity along the length of the bowel and reiterate the importance of judicious prescribing, say the researchers.
 
August 8, 2019
Dupixent is the first and only biologic to show positive results in this paediatric atopic dermatitis population.
A pivotal Phase III trial evaluating Dupixent® (dupilumab) in severe atopic dermatitis in children has met its primary and secondary endpoints. 
 
August 8, 2019
The research, published in Science Advances, involved an international collaboration of the world's leading coeliac disease experts
Distinct markers in the blood of people with coeliac disease have been detected within a few hours of gluten being consumed.
 
The research, published in Science Advances, involved an international collaboration of the world's leading coeliac disease experts.
 
The peer-reviewed study included the Walter and Eliza Hall Institute of Medical Research in Australia, University of Oslo in Norway, and in the US, Massachusetts General Hospital and University of Chicago.